Currently, there are 107.04M common shares owned by the public and among those 104.83M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of 15.11% and 17.36% over the past three months. LIAN shares are trading 7.38% year to date (YTD), with the 12-month market performance up to 124.30% higher. It has a 12-month low price of $1.33 and touched a high of $4.78 over the same period. LIAN has an average intraday trading volume of 27.71 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.08%, 14.27%, and 69.88% respectively.
Institutional ownership of LianBio ADR (NASDAQ: LIAN) shares accounts for 76.56% of the company’s 107.04M shares outstanding.
It has a market capitalization of $514.42M and a beta (3y monthly) value of 0.13. The earnings-per-share (ttm) stands at -$0.82. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.05% over the week and 2.29% over the month.
Analysts forecast that LianBio ADR (LIAN) will achieve an EPS of $LianBio for the current quarter, $4.80 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $LivaNova PLC while analysts give the company a high EPS estimate of $Lichen China Limited. Comparatively, EPS for the current quarter was $Manhattan Bridge Capital, Inc a year ago. Earnings per share for the fiscal year are expected to increase by 176.47%, and -209.62% over the next financial year.
Looking at the support for the LIAN, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on January 03, 2024, with the firm’s price target at $5-$3.
